knowledge -WSS

knowledge

author：entertainment 2025-08-05 16:32:12 - browse：81

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Pig kidney works a record two months in donated body

WSS

Senate panel to vote on hospitals, PBMs, prisoner care

FDA approves updated Covid vaccines

WATCH: Why do bright lights make us see spots?

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Hospitals warn Medicare's drug payment fix is ‘unlawful’

FDA proposes changes to key medical devices approval pathway

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

WHO may add ‘noma' to its list of neglected tropical diseases

DIEP, the 'gold standard' of breast reconstruction, is under threat

Chimpanzees, like humans and whales, get menopause: Study

State Dept. review finds Biden bears some blame for Afghanistan failures

PEPFAR is under serious threat — and so is global health

Supreme Court strikes down use of affirmative action

Food makers to regulators: Ultra

The cancer drug shortage isn’t new — and neither are the solutions

Popular nasal decongestant doesn't actually relieve congestion

Wikipedia

Diverse clinical trials: Why aren’t we there yet?

Traditional Chinese medicine benefits explored in new JAMA study

How medical schools plan to diversify without affirmative action

Senate panel to vote on hospitals, PBMs, prisoner care

How medical schools plan to diversify without affirmative action

PEPFAR is under serious threat — and so is global health

focus

focus

focus

focus